Researchers developed an instrument to identify unmet needs and quality-of-life outcomes for patients with lymphoma.
Researchers sought to determine whether PLM60 with pegaspargase would have efficacy in patients with extranodal natural killer/T-cell lymphoma.
The aim of this trial was to evaluate the efficacy and safety of orelabrutinib with RCHOP in patients with extranodal non-GCB DLBCL.
Long-acting G-CSF can reduce the risk of hospitalization related to febrile neutropenia in patients with DLBCL treated with R-CHOP.
Researchers sought to determine the mortality trends for patients with multiple myeloma over the past few decades.